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Abstract
Background: Chemokines produced by reactive glia drive migration of immune cells and previous studies from our
laboratory have demonstrated that CD19+ B cells infiltrate the brain. In this study, in vivo and in vitro experiments
investigated the role of reactive glial cells in recruitment and survival of B-lineage cells in response to (murine
cytomegalovirus) MCMV infection.
Methods: Flow cytometric analysis was used to assess chemokine receptor expression on brain-infiltrating B cells.
Real-time RT-PCR and ELISA were used to measure chemokine levels. Dual-immunohistochemical staining was used
to co-localize chemokine production by reactive glia. Primary glial cell cultures and migration assays were used to
examine chemokine-mediated recruitment. Astrocyte: B cell co-cultures were used to investigate survival and
proliferation.
Results: The chemokine receptors CXCR3, CXCR5, CCR5, and CCR7 were detected on CD19+ cells isolated from the
brain during MCMV infection. In particular, CXCR3 was found to be elevated on an increasing number of cells over
the time course of infection, and it was the primary chemokine receptor expressed at 60 days post infection Quite
different expression kinetics were observed for CXCR5, CCR5, and CCR7, which were elevated on the highest
number of cells early during infection and decreased by 14, 30, and 60 days post infection Correspondingly,
elevated levels of CXCL9, CXCL10, and CXCL13, as well as CCL5, were found within the brains of infected animals,
and only low levels of CCL3 and CCL19 were detected. Differential expression of CXCL9/CXCL10 and CXCL13
between microglia and astrocytes was apparent, and B cells moved towards supernatants from MCMV-infected
microglia, but not astrocytes. Pretreatment with neutralizing Abs to CXCL9 and CXCL10 inhibited this migration. In
contrast, neutralizing Abs to the ligand of CXCR5 (i.e., CXCL13) did not significantly block chemotaxis. Proliferation
of brain-infiltrating B cells was detected at 7 days post infection and persisted through the latest time tested
(60 days post infection). Finally, astrocytes produce BAFF (B cell activating factor of the TNF family) and promote
proliferation of B cells via cell-to-cell contact.
Conclusions: CXCR3 is the primary chemokine receptor on CD19+ B cells persisting within the brain, and migration
to microglial cell supernatants is mediated through this receptor. Correspondingly, microglial cells produce CXCL9
and CXCL10, but not CXCL13. Reactive astrocytes promote B cell proliferation.
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Background
While it has been well-established that Ab-producing
cells of the B-lineage play a local protective role during
central nervous system (CNS) infection with encephalitic
RNA viruses such as Sindbis virus, Semliki Forest virus,
West Nile virus, rabies virus, and neurotropic corona-
viruses [1–6]; both the beneficial and detrimental contri-
butions of these lymphocytes within the brain following
encephalitis induced by cytomegaloviruses have been
largely ignored. We have previously shown that murine
cytomegalovirus (MCMV) infection triggers accumulation
and persistence of B-lineage cells within the brain, which
produce Abs and play a significant role in controlling
reactivated virus [7]. While the involvement of chemo-
kines and survival factors in B cell migration and differen-
tiation in lymphoid organs is well-documented, little is
known about the glial cell-produced factors which are
involved in the recruitment, retention, and long-term
survival of these lymphocytes within the brain.
Our previous studies have extensively characterized
cytomegalovirus neurotropism both in vitro and in vivo,
reviewed in Cheeran et al. [8]. Using primary cell culture
systems or brain-derived cell lines, it has been shown
that practically all cell types within the brain have some
degree of susceptibility to CMV infection. However,
these different cell types vary in their ability to support a
complete viral replication cycle, which in turn is largely
controlled by the transcription factor milieu within the
cell during infection. In both mice and humans, cultured
primary astrocytes support productive CMV infection
with a 3 log10 unit increase in viral titers over a course
of 5 days. These cells also respond to the virus by produ-
cing immune mediators. In contrast to astrocytes, pri-
mary differentiated neurons and primary microglial cells
are much more refractory to productive CMV replica-
tion. Although nonproductively infected, microglial cells
are stimulated by viral antigens to produce immune me-
diators. It is important to distinguish between productive
viral infection of glial cells and their innate stimulation
by viral antigens through pattern recognition receptors
or immune factors. Our previous in vivo studies have
shown that subsequent to intracerebroventricular (icv)
infection with MCMV, in immunocompetent animals,
viral brain infection is localized primarily to cells that
line the periventricular region. These periventricular tar-
get cells were subsequently identified as nestin-positive,
neural stem cells [9]. Infection spreads to astrocytes within
the brain parenchyma only in the absence of an effective
CD8+ T cell response [10]. Reports by other groups have
also established the importance of CD8+ T cells for control
of primary infection [11, 12]. Likewise, previous studies
from our laboratory have shown that antigen-specific CD8
+ T cells persist within the brain even in the absence of de-
tectable viral protein [13]. Establishment of latency after
clearance of acute infection and the potential to reactivate
to recurrent infection are key features of all herpesvirus,
including MCMV [14].
During normal development of high-affinity Ab-
secreting cells, germinal center plasma blasts give rise to
long-lived plasma cells which reside primarily in the
bone marrow. The bone marrow niche provides factors
necessary to support long-term survival of these cells in
order to maintain serum Ab levels and protect against
re-infection [15, 16]. Because passage of Abs from serum
into the brain through an intact blood–brain barrier is
inefficient, local Ab secretion by cells which have infil-
trated the brain appears to be a more effective strategy
for viral control. Cells of the B-lineage enter the CNS in
response to acute viral infection, and like T cells, they
are retained within the brain into the chronic phase. Al-
though CD8+ T cells play a critical role in controlling
viral spread during acute brain infection [10, 11], pro-
longed immune responses within the brain following
MCMV infection are characterized by persistence of Ab-
producing B cells, chronic microglial cell activation, and
retention of virus-specific memory CD8+ T cells [7, 13].
Like other herpesviruses, MCMV establishes latency
after control of acute infection and clearance of detect-
able viral antigen. We have previously found that Abs
produced within the CNS play a significant role in con-
trolling MCMV reactivation from the latent state [7].
A number of chemokines and their receptors have
been demonstrated to regulate B cell responses in
lymphoid organs [17]. The chemokine receptor CXCR5
(and its ligand CXCL13), as well as CCR7 (and its ligands
CCL19 and CCL21), has been shown to play important
roles in trafficking of B cells to lymphoid follicles in the
development of germinal centers. Specifically within the
CNS, during multiple sclerosis, but not viral infection,
CXCL13 has been associated with formation of ectopic
follicle-like structures and recapitulation of all stages of B
cell differentiation observed in secondary lymphoid organs
[18, 19]. It has also been shown to be a major chemokine
receptor for B cell recruitment to the CNS during several
neuroinflammatory diseases in patients [20]. The chemo-
kine receptor CXCR3 is normally absent on naïve B cells,
but it is upregulated during differentiation into memory
and plasma cell precursors [21]. Furthermore, in knockout
animals, the absence of CXCR3 has been demonstrated
to impair recruitment of Ab-secreting cells into the
CNS in a glia-tropic mouse hepatitis virus (MHV)-JHM
model [22]. Using a Sindbis virus infection model,
CCR5 was detected on 42 % of CD19+ B cells within
the infected CNS, suggesting this receptor may also
have recruiting functions [23].
In the present study, using both in vivo and in vitro
experiments, we examined the production of known B
cell-attracting chemokines by reactive glial cells and
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examined their role in driving B lymphocyte infiltration
and persistence within the brain in response to MCMV
infection. We also examined the role of activated glia in
promoting B cell survival and proliferation.
Methods
Ethical approval
This study was carried out in strict accordance with rec-
ommendations in the Guide for Care and Use of Labora-
tory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal care
and Use Committee (Protocol Number: 140231307A) of
the University of Minnesota.
Virus
RM461, a MCMV expressing Escherichia coli β-
galactosidase under the control of the human ie1/ie2
promoter/enhancer [24], was kindly provided by Edward
S. Mocarski. The virus was maintained by passage in
weanling female Balb/c mice (Charles River, Wilming-
ton, MA). Salivary gland-passed virus was then grown in
NIH 3T3 cells for two passages, which minimized any
carry-over of salivary gland tissue. Infected 3T3 cultures
were harvested at 80 to 100 % cytopathic effect and
subjected to three freeze–thaw cycles. Cellular debris
was removed by centrifugation (1000×g) at 4 °C, and
the virus was pelleted through a 35 % sucrose cushion
(in Tris-buffered saline (TBS), 50 mM Tris–HCl,
150 mM NaCl, pH 7.4) at 23,000×g for 2 h at 4 °C. The
pellet was suspended in TBS containing 10 % heat-
inactivated fetal bovine serum (FBS). Viral stock titers
were determined on 3T3 cells as 50 % tissue culture in-
fective doses (TCID50) per milliliter.
Intracerebroventricular infection of mice
Infection of mice with MCMV was performed as previ-
ously described [25]. Briefly, female C57BL/6 mice
(8 weeks old) were anesthetized using a combination of
ketamine and xylazine (100 mg and 10 mg/kg body
weight, respectively) and immobilized on a small animal
stereotactic instrument equipped with a Cunningham
mouse adapter (Stoelting Co., Wood Dale, IL). The skin
and underlying connective tissue were reflected to ex-
pose reference sutures (sagittal and coronal) on the skull.
The sagittal plane was adjusted such that the bregma
and lambda were positioned at the same coordinates on
the vertical plane. Virulent, salivary gland-passaged
MCMV RM461 (1 × 105 TCID50 units in 10 μl) was
injected into the right lateral ventricle at 0.9 mm lateral,
0.5 mm caudal, and 3.0 mm ventral to the bregma using
a Hamilton syringe (10 μl) fitted to a 27 G needle. The
injection was delivered over a period of 3–5 min. The
opening in the skull was sealed with bone wax, and the
skin was closed using 4-0 silk sutures.
Isolation of brain leukocytes and flow cytometry
Leukocytes were isolated from the brains of the MCMV-
infected C57BL/6 mice using a previously described pro-
cedure with minor modifications [26–28]. In brief, the
whole brains were harvested, pooled (n = 2–4 animals/
group/experiment), minced finely in RPMI 1640 (2 g/l
D-glucose and 10 mM HEPES), and digested in 0.0625 %
trypsin (in Ca/Mg-free Hanks’ balanced salt solution
(HBSS)) at room temperature for 20 min. Single-cell prep-
arations from the brains were suspended in 30 % Percoll
and banded on a 70 % Percoll cushion at 900×g at 4 °C for
15 min. Brain leukocytes obtained from the 30–70 % Per-
coll interface were collected and used for subsequent Ab
staining for flow cytometry. For Ab staining, the brain leu-
kocytes were first treated with Fc block (anti-CD32/CD16
in the form of 2.4G2 hybridoma culture supernatant with
2 % normal rat and 2 % normal mouse serum) to inhibit
nonspecific Ab binding and were stained with anti-mouse
cell surface markers for 45 min at 4 °C (anti-CD45-PE-
Cy5, anti-CD11b-AF700, anti-CD19-FITC, anti-Ki67-
APC, and anti-CD267(TACI)-PE (eBiosciences, San
Diego, CA); and anti-CD269(BCMA)-FITC (R&D Sys-
tems, Minneapolis, MN)). Analysis by flow cytometry
was performed. Control isotype Abs were used for all
fluorochrome combinations to assess nonspecific Ab
binding. Live leukocytes were gated using forward
scatter and side scatter parameters on a BD FACS-
Canto flow cytometer (BD Biosciences, San Jose, CA).
Data was analyzed using FlowJo software (FlowJo,
Ashland, OR).
Immunohistochemistry
The brains were harvested from animals that had been
perfused with a series of phosphate-buffered saline
(PBS), 2 % sodium nitrate, and 4 % paraformaldehyde.
The murine brains were subsequently submerged in 4 %
paraformaldehyde for 24 h and transferred to 25 % su-
crose solution for 2 days prior to sectioning. After block-
ing (10 % normal goat serum and 0.3 % Triton X-100 in
PBS) for 1 h at room temperature (RT), the brain sections
(25 μm) were incubated overnight at 4 °C with the follow-
ing primary Abs: rat anti-mouse CD3 (10 μg/ml; R&D
Systems, Minneapolis, MN) and rat anti-mouse CD19
(15 μg/ml; Biolegend, San Diego, CA). After washing three
times with TBS, secondary Ab (goat anti-rat IgG biotinyl-
ated; Vector Labs, Burlingame, CA) was added for 1 h at
RT followed by incubation with ABC (avidin-biotinylated
enzyme complex, Vector Labs) solution. The peroxidase
detection reaction was carried out using 3,3′-diaminoben-
zidine tetrahydrochloride (DAB; Vector Labs) for several
minutes at RT. Double immunolabeling was performed
using secondary goat anti-rat HRP-conjugated Ab (Vector
Labs) and developed with HistoGreen substrate (Linaris,
Dossenheim, Germany). For double immunofluorescence
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staining, goat anti-mouse CXCL10 (15 μg/ml), CXCL13
(10 μg/ml), and goat anti-BAFF (B cell activating factor of
the TNF family, 15 μg/ml) Abs (R&D Systems) and rabbit
anti-GFAP (glial fibrillary acidic protein, 1:500 dilution;
DAKO, Carpenteria, CA) and rabbit anti-Iba1 (ionized
calcium-binding adaptor molecule 1) (1 μg/ml; Wako
Chemicals, Richmond, VA) Abs were used followed by
donkey anti-goat Alexa Fluor 488 and donkey anti-rabbit
Alexa Fluor 594 Abs with nuclear labeling using Hoechst
33342 (1 μg/ml; Chemicon, Temecula, CA) and viewed
under a fluorescent microscope.
Real-time PCR
RNA from the brain tissue was extracted using TRIzol
reagent (Invitrogen, Carlsbad, CA), respectively. cDNA
was synthesized with 1.0 μg of total RNA using Super-
script III reverse transcriptase (Invitrogen) and oligo
d(T)12–18 primers (Gene Link, Hawthorne, NY). PCR
was performed with the SYBR Advantage qPCR master
mix (ClonTech, Mountain View, CA). The PCR condi-
tions for the Mx3000P QPCR System (Stratagene, now
Agilent Technologies, La Jolla, CA) were as follows: 1
denaturation cycle at 95 °C for 10 s; 40 amplification
cycles of 95 °C for 10 s, 60 °C annealing for 10 s, and
elongation at 72 °C for 10 s, followed by 1 dissociation
cycle. The relative product levels were quantified using
the 2−ΔΔCt method [29] and were normalized to the
housekeeping gene hypoxanthine phosphoribosyl trans-
ferase (HPRT).
Enzyme-linked immunosorbent assay
The murine brains were homogenized in DMEM con-
taining 1 % FBS and were centrifuged at 4 °C for 15 min
to harvest supernatants used in enzyme-linked immuno-
sorbent assay (ELISA). Protein concentrations were mea-
sured using a Bradford assay (Bio-Rad, Hercules, CA).
The supernatants from MCMV- and cytokine-stimulated
astrocyte and microglial cultures (48 h) were collected
for ELISA. In brief, 96-well ELISA plates pre-coated with
anti-mouse CXCL9, CXCL10, CXCL13, CCL3, CCL5,
CCL19, or BAFF Abs (2 μg/ml) overnight at 4 °C were
blocked with 1 % BSA in PBS for 1 h at 37 °C. After
washing (PBS with Tween 20), the supernatants and a
series of diluted standards were added to the wells for
2 h at 37 °C. Detection Abs of anti-CXCL9, CXCL10,
CXCL13, CCL3, CCL5, CCL19, or BAFF were added
for 90 min at 37 °C followed by addition of secondary
Abs conjugated with horseradish peroxidase (1:10,000)
for 45 min at 37 °C. The chromogen substrate K-Blue
(Neogen, Lexington, KY) was added for color develop-
ment which was terminated with 1 M H2SO4. The
plates were read at 450 nm, and chemokine levels
were extrapolated from standard curves and normalized
to protein concentrations.
B cell isolation
The spleens from MCMV-primed (RM461, 1 × 104
TCID50, i.p.) donor animals were collected aseptically at
7 days post-priming. Single-cell suspensions were depleted
of RBC through treatment with 0.87 % ammonium chlor-
ide, washed twice, and cell viability was confirmed using
trypan blue. B lymphocytes were enriched by negative se-
lection using a MagCellect isolation kit following the man-
ufacturer’s instructions (R&D Systems). Isolated B cells
were consistently >99 % CD19+ as evaluated by flow cy-
tometry and had a viability of 99 % as evaluated by trypan
blue dye exclusion.
Chemotaxis assay
B cell migration assays were performed using a 96-well
cell migration system (Neuro Probe, Gaithersburg, MD)
with 5-μm pore size polycarbonate membrane filters.
The isolated B cells suspended in DMEM containing
2 % FBS were loaded onto the upper chambers (2 × 105
cells in 100 μl per well). The lower chambers were filled
with 300 μl of media with or without recombinant che-
mokines or glial cell-conditioned media. After incuba-
tion for 4 h at 37 °C, migrated cells in the lower
chamber were either collected and counted at a high
flow rate for 1 min using flow cytometry or AlamarBlue
dye (10 μl) was added to the lower chamber, incubated
overnight at 37 °C, and read with a fluorescent plater
reader (Ext544 nm/Em590 nm) to assess the number of mi-
grated cells. All assays were performed in triplicates or
quadruplicates. In the blocking experiments, neutralizing
Abs to chemokines were pre-incubated with glial cell-
conditioned media for 30 min at 37 °C prior to being
loaded into the chambers.
Primary glial cell cultures
Murine cerebral cortical cells from 1-day-old mice were
dissociated after a 30-min trypsinization (0.25 %) in
HBSS and plated in 75 cm2 culture flasks in DMEM
containing 6 % FBS, penicillin (100 U/ml), streptomycin
(100 μg/ml), gentamicin (50 μg/ml), and Fungizone®
amphotericin B (250 pg/ml). The medium was replen-
ished 1 and 4 days after plating. On day 12 of culture,
floating microglial cells were harvested and plated onto
48-well cell culture plates (1 × 105 cells/well). After a 1-h
incubation at 37 °C, the culture plates were washed and
incubated overnight before starting the experiments.
Purified microglial cell cultures were comprised of a cell
population in which >95 % stained positively with Iba-1
antibodies and 3–5 % stained positively with antibodies
specific to GFAP. Purified astrocyte cultures were prepared
from the culture flask following isolation of microglia at
14 days in vitro. Briefly, after collection of microglia, the
culture flasks were shaken at 180–200 rpm at 37 °C for
16 h followed by trypsinization (0.25 % trypsin in HBSS)
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for 30 min. After adding FBS (final concentration 10 %),
centrifugation, and washing, the cells were seeded into new
flasks with DMEM followed by a medium change after
24 h. The subculture procedure was repeated weekly for
2–3 times to remove residual oligodendrocytes and micro-
glia in order to achieve highly purified astrocyte cultures
(95–98 % of cells reacted with GFAP Ab, 3–5 % stained
with Iba-1 Ab), which were plated onto 48-well culture
plates (1 × 105 cells/well).
Statistical analysis
Pooled data are presented as mean (±SEM) derived from
independent experiments. Representative data are pre-
sented as mean (±SD) of replicate samples. All statistical
analysis was performed using analysis of variance
(ANOVA) followed by Scheffe post hoc test.
Results
B cells are recruited into the brain and persist following
MCMV infection
Previous studies from our laboratory have identified CD19+
B lymphocytes within the CD45hiCD11blo leukocyte popu-
lation infiltrating the brain in response to MCMV infection
[7, 30]. In this study, multi-color flow cytometry was used
to investigate the recruitment, persistence, and survival of
this leukocyte population. Data generated from these ex-
periments showed that CD19+ B cells entered the brain
early during the course of infection (i.e., by 7 days post in-
fection) and persisted through at least 60 days post infec-
tion, the latest time point tested. At 60 days post infection,
13.46 % of the CD45hiCD11blo leukocytes isolated from
the infected brains were CD19+ (Fig. 1a). The absolute
number of CD19+ cells was calculated from the flow cy-
tometry data (Fig. 1b). Results presented in this study were
obtained using MCMV infection of C57BL/6 mice, which
differs from MCMV infection of the BALB/c animals used
in our previous study [30]. We have directly compared the
B cell brain infiltration and retention kinetics between
these mouse strains. In these studies, the MCMV-infected
BALB/c mice had higher, increasing levels of CNS B cells
over the time course of infection. In contrast, the C57BL/
6 animals had lower, decreasing CNS B cell levels. The
results from these experiments showed 2.5 × 105 CD19+ B
cells within the brain of the BALB/c animals at 30 days
post infection, which is the same level as reported in Mut-
nal et al. [30]. In contrast, in the present study, we found
2.8 × 104 CD19+ B cells within the brains of the C57BL/6




Fig. 1 Long-term persistence of CD19+ B cells within the CNS following MCMV brain infection. Single-cell suspensions of brain tissue obtained
from MCMV-infected mice were banded on a 70 % Percoll cushion. Brain leukocytes were collected and labeled with PE-Cy5-conjugated Abs specific for
CD45, AF700-labeled anti-CD11b, PE-Cy7 anti-CD3, and Cy7-APC anti-CD19 and analyzed using flow cytometry. a Representative histograms show the
percentage of CD45+CD19+ cells within the brain-infiltrating CD45hiCD11bloCD3− population obtained from animals at 7, 14, 30, and 60 days post infection
b Anti-CD19 staining was used to determine the total number of B cells within the infiltrating CD45hi CD3− population. Pooled data are presented as
mean (±SEM) absolute number of infiltrating cells from three independent experiments (n= 6–7 animals/time point). c Immunohistochemical staining
demonstrating persistence of CD19+ B cells (brown), as well as CD3+ T cells (blue) within infected brains at 15 and 60 d.p.i.
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know why these differences exist between the two mouse
strains, but MCMV infection is clearly much more robust
in the BALB/c animals. It is important to point out that
the efficiency of lymphocyte extraction from all tissues, in-
cluding the brain, for flow cytometry may be considerably
less than 100 % [31].
B cell presence within the CNS following viral infection
was further analyzed using immunohistochemical staining.
Thin sections of the brain tissue obtained 15 and 60 days
post infection and stained using Mabs against CD19 con-
firmed the presence of these cells which were localized in
the periventricular region (Fig. 1c). Double-immunostaining
using anti-CD3 along with anti-CD19 Mabs also demon-
strated the presence of T cells within this region (Fig. 1c).
Chemokine receptors are differentially expressed on
brain-infiltrating B cells
B cells are known to express select chemokine receptors
which may be involved in homing to MCMV-infected brain.
Therefore, levels of CXCR3 (receptor for CXCL9 and
CXCL10), CXCR5 (receptor for CXCL13), CCR5 (receptor
for CCL3 and CCL5), and CCR7 (receptor for CCL19) were
analyzed on CD45hiCD11bloCD19+ B cells which infiltrated
the brain at 7, 14, 30, and 60 days post infection. All of these
known B cell chemokine receptors were detected on CD19+
cells isolated from the brain during MCMV infection
(Fig. 2a). In particular, CXCR3 was found to be elevated on
an increasing number of cells over the time course of infec-
tion and it was the primary chemokine receptor expressed
at 60 days post infection (Fig. 2b). Quite different expression
kinetics were observed for CXCR5, CCR5, and CCR7, which
were elevated on the highest number of cells early during in-
fection and decreased by 14, 30, and 60 days post infection
(Fig. 2b). These results suggest that the CXCR3 ligands
(CXCL9 and CXCL10) may be major contributors to B cell
recruitment and persistence within the brain following
MCMV infection. However, the expression level of a particu-
lar chemokine receptor alone may not be a good indicator of
its importance in migration, as other factors such as chemo-
kine levels and ligand affinities are also involved. However,
CXCR3 was the only chemokine receptor which was found






CXCR3+ CXCR5+ CCR5+ CCR7+
B
Fig. 2 Chemokine receptor expression on brain-infiltrating CD19+ B cells. a Representative contour plots show the percentage of CD19+ B cells
isolated from the brains expressing the CXCR3, CXCR5, CCR5, and CCR7 chemokine receptors as assessed using flow cytometry at 7, 14, 30, and
60 increasing proportion of B cells as time b Line graphs display the total number (±SEM) of CD19+CXCR3+, CD19+CXCR5+, CD19+CCR5+, and
CD19+CCR7+ B cells within the brain-infiltrating leukocyte population pooled from two independent experiments (n = 4–5 animals/time point) at
7, 14, 30, and 60 increasing proportion of B cells as time
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(Fig. 2b). In addition to triggering cell migration into the
brain, CXCR3 expression may provide additional B cell mat-
uration and survival functions [32], which may become more
apparent at the later time points as infection progresses.
B cell-attracting chemokines are produced within infected
brains
To characterize the chemokines expressed within the brain
following MCMV infection, chemokine messenger RNAs
(mRNAs) were assessed by real-time RT-PCR. The elevated
levels of CCL5, CXCL9, CXCL10, and CXCL13 transcripts
were detected from the infected brains (Fig. 3a). All of the
upregulated chemokine mRNAs reached peak levels at 7
increasing proportion of B cells as time and declined
substantially at 14 increasing proportion of B cells as time.
The corresponding protein levels of CXCL9, CXCL10, and
CXCL13, as well as CCL5, were also found to be elevated
using ELISA at 7 increasing proportion of B cells as time
(Fig. 3b). In contrast, low levels of CCL3 and CCL19
mRNA were found within the brains of the infected ani-
mals, and only minimal protein levels were detectable using
ELISA (Fig. 3a, b).
Fig. 3 Expression of relevant B cell chemotactic factors within MCMV-infected brains. a Expression of chemokine mRNAs relevant to B cell migration was
detected in a brain using real-time RT-PCR over the indicated time course of infection. Data are expressed as mean ± SEM from two separate experiments
using two animals/time point. b The levels of select chemokine proteins within MCMV-infected (MCMV) brain homogenates were quantified at 7 increasing
proportion of B cells as time using ELISA. Data presented are mean ± SEM from two separate experiments using three animals/group
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Chemokines are co-localized with reactive glia in vivo
To determine the cellular distribution of CXCL10 and
CXCL13 production, we performed dual-immunofluorescence
staining for these chemokines along with specific glial cell
markers on brain tissue sections obtained from animals at
30 increasing proportion of B cells as time. In these studies,
CXCL10 and CXCL13 were both found to co-localize with
GFAP-expressing astrocytes (Fig. 4).
Reactive glial cell cultures produce chemokines
Production of select B cell-attracting chemokines by
primary murine microglial cell or astrocyte cultures stimu-
lated by viral infection (multiplicity of infection (MOI) = 5)
or pro-inflammatory cytokine treatment was assessed using
ELISA at 48 h post-stimulation. Although cultured astro-
cytes do support productive viral infection, it is important
to distinguish between MCMV infection of glial cells and
their innate stimulation by viral antigens through pattern
recognition receptors or immune factors which occur at
the early time points examined. In these experiments, dif-
ferential production of CXCL9/CXCL10 and CXCL13 by
stimulated glial cells activated in response to MCMV infec-
tion was apparent. Microglial cells were found to produce
high levels of CXCL9 and CXCL10 in response to viral in-
fection, while infected astrocyte cultures produced mark-
edly lower levels (Fig. 5). Surprisingly, very low level
production of CXCL13 (as well as CCL19) was detected in
astrocyte cultures stimulated with TNF-α and IL-1β, but
not in response to the virus itself (Fig. 5). Viral infection
also stimulated high levels of CCL3 and CCL5 production
from microglia, but not from astrocyte cultures.
B lymphocytes migrate towards glial cell culture supernatants
Since chemokines produced by reactive glial cells during
viral infection likely serve as signals for leukocyte
chemotaxis into the brain, we went on to assess the abil-
ity of B cells to migrate. We first determined that B cells
obtained from MCMV-primed mice were competent to
move towards the recombinant chemokines CXCL9
(100 ng/ml), CXCL10 (100 ng/ml), and CXCL13
(300 ng/ml) (Fig. 6a and b). Interestingly, no significant
B cell migration to recombinant CCL3, CCL5, or CCL19
(each at 100 ng/ml) was observed (Fig. 6a and b). A
dose–response study demonstrated that these B cells
were competent to move towards high concentrations
(i.e., 100 and 300 ng/ml) of recombinant CXCL13
(Fig. 6c). We next assessed the ability of B lymphocytes
to migrate towards supernatants obtained from stimu-
lated or MCMV-infected microglial cell and astrocyte
cultures placed in the lower wells of a chemotaxis cham-
ber. Significant migration of B cells towards interferon
(IFN)-γ-stimulated astrocyte supernatants was seen
(Fig. 6d). In addition, B cells were found to move to-
wards supernatants from MCMV-infected microglial
cells, but not astrocytes (Fig. 6d). Pretreatment of the in-
fected microglial cell supernatants with neutralizing Abs
to CXCL9 and CXCL10 significantly blocked B cell mi-
gration (Fig. 6e). Neutralizing Abs to the ligand of
CXCR5 (i.e., CXCL13) did not significantly block
chemotaxis. The results indicated that, although these B
cells were competent to move towards high concentra-
tions of recombinant CXCL13, their migratory response
to supernatants from infected microglia was primarily
mediated through CXCR3 (Fig. 6e).
Fig. 4 Immunohistochemical staining for chemokine production by reactive glia. Twenty-five-micrometer sections of the brain tissue
obtained from MCMV-infected animals at 30 increasing proportion of B cells as time were immunostained using Abs against CXCL10
(green) and CXCL13 (green) along with GFAP (red) to identify astrocytes producing these chemokines in vivo. Merged images demonstrate
chemokine production localized to astrocytes
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B cells proliferate within the brain
BAFF and a proliferation-inducing ligand (APRIL) are well-
known activating and survival factors for cells of the B-
lineage and are essential for their long-term maintenance
in the bone marrow [33]. Therefore, long-term mainten-
ance of this population in the CNS also suggests the pres-
ence of these survival factors [6, 34]. We have previously
reported the presence of BAFF and APRIL mRNA expres-
sion within MCMV-infected brains [7]. To determine
whether B cells within the CNS were proliferating, we ex-
amined these cells for the presence of Ki67, which is
present in the nuclei of proliferating or recently proliferated
cells, but not in quiescent cells. Results from these studies
showed that B cells within the infected brains demon-
strated proliferation at early time points (14.4 %, 7 increasing
proportion of B cells as time), as well as sustained prolifera-
tion persisting through the latest time point tested (21.9 %,
60 increasing proportion of B cells as time) (Fig. 7a). We
confirmed the upregulation of BAFF mRNA expression
within the brains of MCMV-infected mice (Fig. 7b). In
addition, dual-immunofluorescence staining for BAFF pro-
tein (CD257) and GFAP demonstrated that astrocytes were
a source of BAFF within the CNS at 30 increasing propor-
tion of B cells as time (Fig. 7c). We went on to examine
BAFF receptor (BAFFR) expression on CD19+ B cells within
the infected brains by gating on the CD45hiCD11bloCD19+
population of infiltrating leukocytes followed by analysis at
7, 14, 30, and 60 increasing proportion of B cells as time
(Fig. 7d). The data obtained by flow cytometry were then
used to calculate the total number of brain-infiltrating B
cells expressing BAFFR at each time point p.i. (Fig. 7e).
Additional flow cytometry experiments were performed to
assess transmembrane activator and CAML interactor
(TACI) and B cell maturation antigen (BCMA) on brain-
infiltrating B cells at both early (7 increasing proportion of
B cells as time) and late (60 increasing proportion of B
cells as time) time points post-infection (Fig. 7f).
Astrocytes promote survival and proliferation of CD19+ B
cells in vitro
To investigate the capacity of glial cells to promote B cell
survival, we examined primary cell cultures for BAFF
production in response to stimulation with MCMV or pro-
inflammatory cytokines (Fig. 8a). BAFF was found to be pri-
marily produced by IFN-γ-stimulated astrocytes, with much
lower production by microglial cells. We then isolated B
cells from MCMV-primed β-actin promoter-luciferase
transgenic mice (7 days post-priming) and added these cells
Fig. 5 Production of B cell chemotactic factors following viral infection and cytokine stimulation of cultured primary murine microglial cells and
astrocytes. Primary murine microglial cell (black bars) or astrocyte (gray bars) cultures in 48-well plates (1 × 105 cells/well) were infected with
MCMV (MOI = 5) or stimulated with the indicated pro-inflammatory cytokine (i.e., TNF-α and IL-6, 20 ng/ml; IL-1β and IFN-γ, 10 ng/ml; IFN-α and
IFN-β, 200 U/ml) for 48 h. Production of select B cell-attracting chemokines was assessed using ELISA. Pooled data are presented as mean ± SEM
from three to four independent experiments
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to primary murine astrocyte cultures. Because β-actin
promoter-luciferase transgenic mice ubiquitously express
the luciferase enzyme, reduced luciferin intensity, as assessed
using relative light units (RLU), was indicative of cellular
toxicity. When co-cultured with astrocytes at a ratio of 10:1,
luciferase-expressing B cells demonstrated prolonged sur-
vival over the 7-day time course when compared to CD19+
cells cultured alone (Fig. 8b). In addition, when the co-
cultured cells were analyzed using flow cytometry, the
CD19-gated population displayed enhanced proliferation over
B cells without astrocytes (28.8 versus 4.55 % following 4 days
of co-culture), as indicated through staining for Ki67 (Fig. 8c).
When conditioned media from astrocyte cultures was used
alone (i.e., no co-culture), 7.9 % of the B lymphocytes were
found to proliferate at 1 day and 1.3 % were Ki67 positive at
4 days. These results indicate that astrocytes promote
proliferation of B lymphocytes through a mechanism requir-
ing cell-to-cell contact. However, clearly, astrocytes are not the
only cell type which can enhance B cell survival and their sur-
vival is likely not dependent on the presence of BAFF.
Discussion
In our previous study, we detected cells of the B-lineage
which entered the brain in response to MCMV infection,
produced anti-viral Abs, and persisted for at least 30 in-
creasing proportion of B cells as time [7]. Here, we ex-
amined the kinetics of B cell recruitment into the brain
mediated through chemokine production by reactive
glia, along with their survival and persistence until at
least 60 increasing proportion of B cells as time. Our
previous study demonstrated that CD19+ B cells which had
undergone further differentiation into CD19−CD38+CD138+
Fig. 6 B cell migration towards recombinant chemokines and supernatants from stimulated glial cell cultures. CD19+ cells were isolated from the spleens of
the MCMV-primed mice (7 days), and migration was assessed using chemotaxis chambers. aMigration of B cells towards select recombinant chemokines
(100 ng/ml; 300 ng/ml for CXCL13). After 4 h, the migrated cells were stained using Alamar blue and read with a fluorescent plate reader (Ex550 nm Em590 nm).
**p<0.0001 vs. media alone. b Total numbers of migrated CD19+ cells were determined using flow cytometry. Data (mean± SD) presented are representative
of three independent experiments. **p=0.0034 for CXCL9 and **p< 0.0001 for CXCL10 and CXCL13 vs. media alone. c B cell migration to recombinant CXCL13
(dose 0 to 300 ng/ml). Pooled data are (mean± SEM) derived from two independent experiments. **p=0.0038 for 100 ng/ml and **p< 0.0001 for 300 ng/ml
vs. 0 ng/ml. d Migration of B cells towards culture supernatants obtained from IFN-γ-stimulated (10 ng/ml) or MCMV-infected (MOI = 5) primary microglial cell
and primary astrocyte cultures at 48 h post-stimulation or infection. B cell migration was assessed after 4 h by flow cytometry. Data (mean ± SD) shown
are representative of two separate experiments. **p < 0.0001 for astrocytes vs. untreated and **p = 0.0044 for microglia vs. untreated. e Blockade of
specific migration towards MCMV-infected (MOI = 5) microglial cell supernatants. Anti-chemokine Abs were added (10 μg/ml) to supernatants from
infected microglial cell cultures for 1 h prior to being loaded onto the chemotaxis chamber for assessment of effects on migration. B cell migration
was assessed after 4 h by flow cytometry. Pooled data are (mean ± SEM) derived from two independent experiments. ††p = 0.0083 vs. MCMV alone























Fig. 7 Sustained proliferation of B cells within the CNS following MCMV infection. a B cell proliferation within the infected brains was detected by
gating on the CD45hiCD11bloCD19+ population of infiltrating leukocytes followed by analysis of Ki67 (anti-Ki67-APC) expression at 7, 14, 30, and
60 increasing proportion of B cells as time. Histograms presented are representative of two independent experiments. b Expression of transcripts
for the B cell activating factor BAFF was assessed in RNA extracted from the brains of the infected animals at the indicated time points p.i. Data
presented are mean ± SEM of two separate experiments. c Immunohistochemical staining showing expression of BAFF protein (CD257) within the
brain co-localized to GFAP-expressing astrocytes. Twenty-five-micrometer sections of the infected brain shown were obtained at 30 increasing
proportion of B cells as time d BAFFR expression on CD19+ B cells within infected brains was detected by gating on the CD45hiCD11bloCD19+
population of infiltrating leukocytes followed by analysis of BAFFR expression at 7, 14, 30, and 60 increasing proportion of B cells as time. Histo-
grams presented are representative of two independent experiments. e Anti-BAFFR staining was used to determine the total number of B cells
expressing BAFFR at the indicated time points p.i. Data (mean ± SD) are presented as absolute number of cells. f Anti-TACI and anti-BCMA staining
was used to analyze expression of these receptors on brain-infiltrating B cells using flow cytometry at the early (7 d) and late (60 day) time points
p.i. Histograms presented are representative of two independent experiments, and data presented are mean percentages from two animals per
time point
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plasma cells were present within the brain along with CD19+
B cells. It is well-established that CD19+CD38+CD138+
plasma blasts down-regulate expression of CD19 as they
fully differentiate into mature plasma cells, but at this
point, it is unknown whether this CD19 down-regulation
occurs prior to entry into the brain or after the cells have
been recruited. Since in this study we wanted to investi-
gate chemokine production by glial cells early during in-
fection and its interaction with chemokine receptors
during the initial recruitment of B cells into the brain,
these experiments were conducted using CD19+ B cells.
The prominent and sustained expression of CXCR3 on
infiltrating CD19 B cells over the course of infection is
consistent with the high-level detection of its ligands
CXCL9 and CXCL10 in brain homogenates using ELISA.
The IFN-γ-inducible CXCR3 ligands CXCL9, CXCL10,
and CXCL11 have previously been reported to mediate
plasma blast migration in vitro [35]. Additionally, within
the CNS, CXCR3-dependent plasma blast migration into
the murine spinal cord during neurotropic coronavirus-
induced encephalomyelitis has also been reported [22].
The results presented here demonstrate that the chemo-
kines CXCL9 and CXCL10 were produced in response to
viral infection of microglial cells, but not in response to
viral infection of primary astrocytes. Likewise, B cells
moved towards supernatants from MCMV-infected
microglia cells, but not towards those obtained from
MCMV-infected astrocytes. However, astrocytes were
shown to be competent to produce these chemokines in
response to stimulation with select pro-inflammatory cy-
tokines. Previous studies investigating IFN-γ-induced















Fig. 8 Glial cells promote survival and proliferation of CD19+ B cells. a IFN-γ treatment stimulates BAFF production by primary murine astrocytes.
Astrocyte and microglial cell cultures were stimulated with MCMV or the indicated pro-inflammatory cytokine (i.e., TNF-α and IL-6, 20 ng/ml; IL-1β
and IFN-γ, 10 ng/ml; IFN-α and IFN-β, 200 U/ml). BAFF levels in the culture supernatants were assessed at 48 h post-stimulation using ELISA. Pooled
data (mean ± SEM) presented are derived from four independent experiments. b CD19+ B cells obtained from MCMV-primed β-actin-luciferase
transgenic mice were cultured in the presence (closed circles) or absence (open circles) of primary murine astrocytes obtained from wild-type
animals at a ratio of 10:1. Cultures were maintained for 0, 1, 4, and 7 days post-reconstitution, and B cell survival was assessed via luminescence. Data
are presented as mean RLU (relative light units) ± SD from triplicate samples and are representative of two independent experiments. c Enhanced
proliferation of B cells (CD19 gated) during co-culture with primary astrocytes was detected following staining with anti-Ki67-APC Abs and flow
cytometry at 1 and 4 days post-reconstitution. Histograms shown are representative of two independent experiments
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results. Myeloid transcription factor PU.1-mediated IFN-γ
induction of CXCL9 has been reported to be limited to
murine microglial cells and not astrocytes [36]. However,
IFN-γ has also been reported to induce this chemokine in
primary human astrocytes [37]. Differences in cell culture
conditions may play a role. It appears that the cellular
source of CXCL10 production depends on both viral trop-
ism and the cytokine milieu present within the infected
brain. It is likely that cytokines produced during T cell in-
filtration into the brain (e.g., IFN-γ expression) activate as-
trocytes to produce chemokines which then drive
subsequent infiltration of B cells. This idea would be con-
sistent with our previous detection of IL-21 mRNA within
MCMV-infected brains at 7, but not 30, increasing pro-
portion of B cells as time [7].
Microglial cells were not identified as a source of CXCL13
using any of the stimuli tested, but reactive astrocytes were
found to be a source of this chemokine, both in vivo and in
vitro. Using ELISA, we found elevated levels of CXCL13
within the brains of the MCMV-infected animals at 7 in-
creasing proportion of B cells as time, but pretreatment of
microglial cell supernatants with anti-CXCL13 Abs did not
inhibit the migration of CD19+ B cells. Likewise, using
knockout animals, CXCL13 has been reported to be dis-
pensable for the initial recruitment of B cells to CNS inflam-
mation induced by either Sindbis virus infection or
experimental autoimmune encephalomyelitis [38].
Taken together, despite its importance in peripheral
lymphoid tissue, it appears that CXCL13 may not be
critical for B cell recruitment into the inflamed brain.
Glial cell-produced survival factors are well-known to
play important roles in retention and survival of B
lymphocyte lineage cells in the brain. BAFF [39, 40],
APRIL [41, 42], and IL-6 have all been identified as
critical factors for B cell differentiation and long-term
survival [6]. We have previously reported the presence of
BAFF and APRIL transcripts within the brain at 30 in-
creasing proportion of B cells as time [7]. Data reported
here are in agreement with previous studies using other
neurotropic viruses which have localized in vivo BAFF
production to astrocytes [6, 34], with production being
highly inducible by IFN-γ.
Results obtained during this study demonstrate that B
cells proliferated within the brain following MCMV in-
fection until at least 60 increasing proportion of B cells
as time. The proliferation of B cells in response to viral
CNS infection has been reported in other models, as de-
tected by Ki67 staining in Sindbis virus-infected mice
[23]. Unlike the situation reported in multiple sclerosis
[19, 43, 44], in this study, we did not observe ectopic
lymphoid follicle-like structures within the infected
brains. They were also not observed in the Sindbis virus
model, so it is possible that they are not a consequence
of viral encephalitis. Additionally, in vitro data show that
astrocytes support B cell proliferation and survival when
they are co-cultured at a 10:1 (B cell to astrocyte) ratio.
Interestingly, astrocytes were shown to express BAFF
(CD257), and brain-infiltrating B cells were shown to ex-
presses BAFFR. Additionally, expression of TACI
(CD267) was detected on 11.2 % of the brain-infiltrating
B cells at 60 increasing proportion of B cells as time,
along with low levels of BCMA (CD269). Like BAFFR,
both of these receptors have been shown to bind BAFF
and promote survival of B cell populations [45–47]. Fi-
nally, conditioned media from the astrocyte cultures
alone did not potentiate B cell proliferation, indicat-
ing that B cells require cell-to-cell contact with as-
trocytes to maximize their proliferation.
Conclusions
Glial cell-induced changes in the brain microenviron-
ment promote the recruitment and survival of B-lineage
cells following MCMV brain infection. Our results reveal
that CXCR3 is the primary chemokine receptor on
CD19+ B cells that persist within the brain following in-
fection. B cell migration towards MCMV-stimulated
microglial cell supernatants is largely mediated through
this receptor. Correspondingly, microglial cells produce
high levels of CXCL9 and CXCL10, but not CXCL13, in
response to viral stimulation. Finally, reactive astrocytes
were found to promote B cell survival and proliferation
following MCMV infection.
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